Nicole Dale

About

Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.

Areas of Expertise

Published content

Read FDA vs EMA Drug Labelling for Global Medical Safety
- Labelling and Packaging
- Pharmacovigilance & Safety
- Harmonisation Standards
- Pharmacovigilance
- FDA
- European Medicinces Agency
- Global Regulatory Affairs
- Pharma Regulation
- Regulatory Submissions
- Regulatory Consultation
- Regulatory & IP
- Regulatory Warning Letters
- Pharma Policy
- Post-market
- Commercialisation & Medical Affairs
- Commercial Strategy
- Common Technical Document
- Medical Writers
- Clinical Research Organisations
- Clinical Evidence
- Clinical Data
- Digital Ecosystems
- Data Quality
- Data Protection
- Data Integrity
- Real-World Data
- Real-world Evidence
- Pricing and Market Access
- Multinational Trials
- Drug Approval
- Documentation
- Patient Access
- Patient Care
- pharmaceutical industry
- Pharmaceutical Compliance
- Pharma Intelligence
- Adverse Event Monitoring
- Adverse Events
- Health Surveillance
- Patient Registries
- Medical Governance
- Oncology
- Oncology & Radiotherapeutics
- Oversight
- Medtech
- Digital Health
- Digital Health Technology
FDA vs EMA Drug Labelling for Global Medical Safety
Read Pharmaceutical Packaging for Patient Safety
- Pharmaceutical Manufacturing
- Labelling and Packaging
- Safety & Toxicology
- Pharmacovigilance & Safety
- Adverse Events
- Continuous Manufacturing
- Sterile Manufacturing
- Cold Chain
- Patient Care
- Pharma Supply Chains
- Supply Network Strategy
- Manufacturing Technology
- Continuous Improvement
- Pharma Regulation
- Regulatory & IP
- Formulation
- Contract Manufacturing (CDMO/CMO)
- Quality
- Quality Assurance
- Trial Operations & CMC
- Technical Operations
- Sustainability
- Digital Ecosystems
- Data Quality
- Containment
- Good Manufacturing Practice
- Biologics
- Pharmacovigilance
Pharmaceutical Packaging for Patient Safety
Read FDA’s AEMS Updated for Consolidated Adverse Event Monitoring
- Pharmacovigilance & Safety
- FDA
- Adverse Event Monitoring
- Pharmacovigilance
- Adverse Events
- Regulatory Submissions
- Pharma Regulation
- Regulatory & IP
- Pharma Policy
- Commercial Strategy
- Data Analysis
- Data Integrity
- Data Management
- Data Quality
- Electronic Data Capture
- Real-World Data
- Data Protection
- Digital Ecosystems
- AI Pharma
- AI and Automation
- AI & Machine Learning
- Medical Writers
- Medical Governance
- Documentation
- Commercialisation & Medical Affairs
- Labelling and Packaging
- Pharma Intelligence
- Oversight
- Clinical Research Organisations
- Clinical Data
- Clinical Evidence
- Technical Operations
- Quality
- Quality Assurance
- Pharmaceutical Compliance
- Transparency
- Health Surveillance
- Analytical Monitoring
- Patient Access
- Post-market
- Real-world Evidence
- Remote Monitoring
FDA’s AEMS Updated for Consolidated Adverse Event Monitoring
Read The UK’s AI Biosecurity Lab Puts Pharma at the Centre of Security
- Biosecurity
- AI governance
- Infectious Diseases and Vaccines
- Antimicrobials and Anti-infectives
- AI Pharma
- AI & Advanced Healthcare
- AI & Machine Learning
- AI Drug Development
- Machine Learning in Pharma
- LLMs in Pharma
- Pharma Intelligence
- Tech and Innovation
- Biotech
- Data Analysis
- Data Protection
- Research Data
- Health Surveillance
- Biomedical R&D
- pharma R&D
- Pharmaceutical R&D
- Oversight
- Pharma Policy
- Regulatory & IP
- Pharma Regulation
- MHRA
- Computational Biology
- Multiomics
- Research Informatics
- Research Funding
- Translational & Pre-clinical Research
- Preclinical Development
- Nonclinical Development
- AI vendor assessment
- AI vendor auditing
The UK’s AI Biosecurity Lab Puts Pharma at the Centre of Security